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Aza-deoxycytidine induces apoptosis or
differentiation via DNMT3B and targets
embryonal carcinoma cells but not their
differentiated derivatives
P Wongtrakoongate*,1,2, J Li1,3 and P W Andrews1
1Centre for Stem Cell Biology, University of Sheffield, Sheffield S10 2TN, UK
Background: Teratocarcinoma is a malignant male germ cell tumour, which contains stem cells and differentiated cancer tissues.
DNMT3B has been shown to be highly expressed in human teratocarcinoma stem cells, and to mediate cytotoxicity of Aza-
deoxycytidine (Aza-dC) in a pluripotent stem cell line NTERA2.
Methods: We have established DNMT3B or POU5F1 (hereafter referred to as OCT4) knockdown in teratocarcinoma stem cells
N2102Ep and TERA1 and in the pluripotent NTERA2 by a doxycycline-inducible system, and tested the cytotoxicity induced by Aza-dC.
Results: Silencing of DNMT3B led to apoptosis of human teratocarcinoma stem cells N2102Ep and TERA1. Further, we found that
induction of apoptosis or differentiation in NTERA2 and human embryonic stem cells by Aza-dC requires DNMT3B. To test
whether Aza-dC inhibits proliferation of differentiated teratocarcinoma cells, we depleted OCT4 expression in N2102Ep
and TERA1 cells treated with Aza-dC. Treatment with Aza-dC reduced cell number of differentiated cells to a lesser extent than
their undifferentiated parental stem cells. Moreover, in contrast to the stem cells, Aza-dC failed to induce apoptosis of
differentiated cells.
Conclusions: Our finding suggests that DNMT3B acts as an antiapoptotic gene in teratocarcinoma stem cells, and mediates
apoptosis and differentiation of human pluripotent stem cells induced by Aza-dC, and that Aza-dC specifically induces apoptosis
of teratocarcinoma stem cells.
Teratocarcinoma is one form of testicular germ cell tumour (GCT),
the most common type of cancer occurring in young men between
20 and 40 years of age (Oosterhuis and Looijenga, 2005). These
tumours contain both embryonal carcinoma (EC) cells, which
represent the stem cells of the cancer, and a heterogeneous mixture
of their differentiated derivatives. However, in some cases, these
tumours may be composed entirely of EC cells, without any
differentiated cell components, whereas many cell lines such as
N2102Ep and TERA1 derived from testicular GCTs also appear to
be composed of EC cells that have lost the ability to differentiate.
Such EC cells are termed ‘nullipotent’ and fail to differentiate
under normal circumstances such as when grown as xenograft
tumours or induced with agents like retinoic acid (Andrews et al,
1980), which do induce the differentiation of pluripotent EC cell
line NTERA2 (Andrews, 1984; Andrews et al, 1984). The
appearance of nullipotent EC cells may reflect selection of more
aggressive variants during cancer progression. Nevertheless,
nullipotent EC cells can be induced to differentiate following
genetic manipulation to knockdown expression of OCT4 (Matin
et al, 2004; Andrews et al, 2005).
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The cellular origin of GCT has been suggested by Skakkebaek
and colleagues (Skakkebaek, 1972; Rajpert-De Meyts et al, 1998) to
be carcinoma in situ (CIS), also known as intratubular germ-cell
neoplasia unclassified lesion or testicular intratubular neoplasia.
In addition, Rajpert-de Meyts and Hoei-Hansen (Rajpert-de Meyts
and Hoei-Hansen, 2007) have proposed a hypothesis suggesting
that these CIS cells are defective arrested primordial germ cells
(PGCs) or gonocytes due to testicular dysgenesis. A transcriptomic
analysis of CIS, early germ cells and several types of GCTs has
indicated that CIS cells in fact resemble to PGCs/gonocytes (Sonne
et al, 2009). The molecular similarity between CIS and gonocytes is
further supported by low levels of DNA methylation and histone
H3 lysine 9 dimethylation in CIS, which are consistent with low
levels of those epigenetic marks in PGCs (Almstrup et al, 2010). An
activation of embryonic programme similar to embryonic stem
(ES) cells in CIS might lead to the development of teratocarcinoma
stem cells (Almstrup et al, 2004; Skotheim et al, 2005; Kristensen
et al, 2008; Alagaratnam et al, 2012).
Tumour eradication of teratocarcinoma can be achieved by
treatment of those cancers with irradiation and cisplatin-based
compounds, as they are sensitive to these therapies. The sensitivity
of teratocarcinoma to radiation and DNA-damaging agents can be
explained by their cell origin of the tumours, that is, CIS. As these
agents are very toxic to embryonic cells including PGCs, CIS-
derived cancer cells are therefore susceptible to these treatments.
Thus, the loss of a stem cell phenotype of EC cells as they
differentiate to form teratomas will result in a resistance of the
cancers to radiation and chemotherapy (Oosterhuis and Looijenga,
2005). More than 70% of patients with teratocarcinoma can be
cured by using cisplatin-based chemotherapy in combination with
surgery. Nevertheless, the rest of patients cannot be cured due to an
incomplete response or relapse. Moreover, testicular GCT is still a
fatal cancer disease in approximately 5% of the patients. One
potential chemotherapy to improve the treatment outcome is by
combining cisplatin-based therapy with a DNA methylation
inhibitor Aza-deoxycytidine (Aza-dC; Beyrouthy et al, 2009),
which has been clinically used for treatment of patients with
myelodysplastic syndrome and some solid tumours (Yang et al,
2010), and possesses an ability to inhibit proliferation of cancer
stem-like cells (Tsai et al, 2012).
A number of gene expression analyses have found that
DNMT3B, which encodes a de novo DNA methyltransferase, is
highly expressed in nulipotent human EC cells at a level similar to
the pluripotent EC cell line, NTERA2, and human ES cells (Sperger
et al, 2003; Skotheim et al, 2005; Alagaratnam et al, 2012). In the
present study, we found that silencing of DNMT3B induced
apoptosis of nullipotent EC cells, N2102Ep and TERA1. However,
DNMT3B knockdown did not induce apoptosis in pluripotent
NTERA2 and ES cells, but did attenuate apoptosis or differentia-
tion induced by Aza-dC in NTERA2 and ES cells, suggesting that
DNMT3B is required for apoptosis or differentiation induced by
Aza-dC. However, when N2102Ep and TERA1 were caused to
differentiate by a knockdown of POU5F1 (hereafter referred to as
OCT4) Aza-dC-induced apoptosis was antagonised. Our studies
suggest differential roles of DNMT3B in nullipotent and
pluripotent stem cells, and highlight an evidence of cancer stem
cells, but not their differentiated derivatives, which undergo
apoptosis induced by the epigenetic drug.
MATERIALS AND METHODS
Cell culture. Human teratocarcinoma stem cells N2102Ep and
TERA1 (Andrews et al, 1980) and NTERA2 (Andrews et al, 1984)
were grown using DMEM (high glucose, no pyruvate) (PAA)
supplemented with 10% fetal calf serum (FCS; Hyclone, Rockford,
IL, USA). N2102Ep and TERA1 were passaged by 0.25% trypsin/
EDTA at day 5 of culture as previously described (Andrews et al,
1980), whereas NTERA2 were passaged at 1 : 3 ratio by using glass
beads. The human ES cell line H7 (Thomson et al, 1998) was
grown in knockout-DMEM supplemented with 20% knockout-
serum replacement, 1X non-essential amino acids, 1mM glutamine,
0.1mM beta-mercaptoethanol and 4 ngml 1 bFGF (Invitrogen,
Grand Island, NY, USA) seeded on 6 103 cells cm 2 mitomycin
C-treated MF-1 mouse embryonic fibroblasts, and placed at 37 1C
under a humidified atmosphere of 5% CO2 incubator. Cells were
passaged every 5–7 days using collagenase type IV (Invitrogen) and
scraped with glass beads (Sigma, St Louis, MO, USA). For Aza-dC
treatment, cells were grown in medium supplemented with 10 nM
Aza-dC (Sigma); cultures were maintained for 7 days during which
the culture medium was changed every other day.
Establishment of shRNAi-inducible cell lines. Tetracycline
repressor (TetR)-overexpressing cell lines N2102Ep, TERA1 and
NTERA2 were established by transfecting 1 106 cells with 5 mg
pCAG-TetRnls-IRES-Puromycin (Zafarana et al, 2009). Transfec-
tants were seeded on 90mm2 cell culture dishes. Puromycin-
resistant colonies were selected using 3mgml 1 puromycin
(Sigma). Stable TetR-over-expressing N2102Ep, TERA1 and
NTERA2 cell lines were subsequently transfected with 5 mg
pSuperior-Neo (Oligoengine, Seattle, WA, USA) containing siRNA
targeting DNMT3B (Wongtrakoongate et al, 2014). N2102Ep and
TERA1 cell lines harbouring OCT4 shRNAi construct were also
established using the previously reported OCT4 target sequence
(Zafarana et al, 2009). Stable transfected stem cell colonies were
selected using 750 mgml 1 G418 (Invitrogen). Reverse transcrip-
tion quantitative polymerase chain reaction and western blotting
were employed to validate expression of knockdown-target genes
in cells grown with or without 1mgml 1 doxycycline (Dox).
Cloning-efficiency assay. Cells were washed once with PBS.
N2102Ep and TERA1 were disaggregated to a single-cell level
using 0.25% trypsin, whereas 0.05% trypsin was used for NTERA2
and human ES cells H7. Cells were plated at 250 cells (for human
teratocarcinoma stem cells) or at 10 000 cells (for human ES cells)
in six-well plates. After a 2-week culture, cells were washed once
with PBS and ice-cold methanol, respectively. Cells were fixed with
1ml of the methanol for 15min at room temperature. The
methanol was removed, and cells were incubated with 1ml of a
crystal violet solution (0.4% (w/v) in methanol) for another 15min.
Unstained crystal violet was washed off by tap water. The plates
were dried and were counted for colony numbers.
Flow cytometry. Flow cytometry was performed as previously
described (Draper et al, 2002). Briefly, cultured cells were harvested
by trypsinisation. One hundred thousand cells in 100 ml PBS with
10% FCS were treated with MC631 monoclonal antibody
recognising the SSEA3 antigen (Shevinsky et al, 1982) at 1 : 10
dilution for 15min. Cells were then washed and were incubated
with Cy5-conjugated anti-rat secondary antibody (Jackson Labora-
tory, West Grove, PA, USA) for 15min. Cells were washed with
Annexin V binding buffer (Invitrogen), and were incubated with
FITC-conjugated Annexin V for 30min at room temperature. The
samples were analysed with the Cyan flow cytometer (Dako
Cytomation, Carpinteria, CA, USA).
Reverse transcription quantitative polymerase chain reaction.
RNA was extracted using TRIzol reagent (Invitrogen). Comple-
mentary DNA synthesis was performed with 1 mg RNA using
SuperScript II Reverse Transcriptase (Invitrogen). Then, qPCR was
carried on by using SYBR Green JumpStart Taq ReadyMix (Sigma)
in a total volume of 20 ml each well with an iCycler iQ system
(Bio-Rad, Hercules, CA, USA). Primer sequences are available
upon request.
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Western blotting. Cell pellets were resuspended in RIPA buffer
and were subjected to sonification. Protein concentration was
determined using a bicinchoninic acid protein assay kit (Thermo
Scientific, Rockford, IL, USA). Each well was loaded with 20 mg of
proteins. Proteins were transferred to PVDF membrane (Bio-Rad).
Antibodies for western blotting are as followed; DNMT3B
(sc-20704) and OCT4 (sc-5279) from Santa Cruz (Dallas, TX,
USA); ACTB (A5316) from Sigma.
RESULTS
DNMT3B is important for clonal propagation of EC cells. To
ascertain whether DNMT3B might be important for survival of
human EC cells, we have generated Dox-inducible DNMT3B
knockdown in human teratocarcinoma stem cell lines N2102Ep
and TERA1 (Andrews et al, 1980). In addition, we have also
established the inducible DNMT3B knockdown using a pluripotent
stem cell line NTERA2, which possesses a unique ability to
differentiate by retinoic acid (Andrews, 1984). We show that the
expression of DNMT3B was decreased upon induction of Dox
(Figure 1A). The human ES cell line H7 harbouring the DNMT3B
inducible knockdown cassette, which has been established
previously (Wongtrakoongate et al, 2014), also downregulated
expression of DNMT3B by Dox treatment (Figure 1A). This result
indicates that DNMT3B expression level can be silenced by the
Dox-inducible shRNAi.
Next, we performed cloning-efficiency assay to determine
whether DNMT3B might facilitate clonal propagation of terato-
carcinoma stem cells. The clonal ability test reveals that silencing of
DNMT3B led to a reduction of cloning efficiency of EC cells
N2102Ep and TERA1 (Figure 1B), suggesting a role of DNMT3B
in clonal propagation of the cancer stem cells. Similarly, DNMT3B
knockdown also reduced clonal ability of human pluripotent stem
cells NTERA2 and H7 (Figure 1B).
Aza-dC impairs clonal propagation via DNMT3B. DNMT has
been proposed to mediate DNA mutagenicity and hence cellular
cytotoxicity induced by Aza-dC through a covalent trapping
mechanism between Aza-dC-incorporated DNA adduct and the
methyltransferase (Juttermann et al, 1994; Jackson-Grusby et al,
1997). To define whether Aza-dC treatment might diminish colony
survival, and whether DNMT3B might mediate the cytotoxic effect
in human nullipotent EC cells, N2102Ep and TERA1, and human
pluripotent stem cells NTERA2 and H7, DNMT3B expression was
silenced for 3 days, and the cells were subsequently treated with
Aza-dC. The result shows that Aza-dC treatment reduced cloning
efficiency of the stem cells to a greater extent than the DNMT3B
knockdown (Figure 1B). Upon Aza-dC treatment, we found that
further downregulation of DNMT3B by shRNAi elevated colony-
forming numbers in the stem cells, indicating that Aza-dC impedes
survival of the cancer stem cells and pluripotent stem cells partly
through a mechanism involving DNMT3B.
DNMT3B acts as an antiapoptotic gene in human EC cells.
Next, apoptosis assay using a double staining of Annexin V
together with the stem cell marker SSEA3 was employed to
elucidate whether silencing of DNMT3B induces apoptosis of
human nullipotent stem cells N2102Ep and TERA1 and plur-
ipotent stem cells NTERA2 and H7. Upon DNMT3B silencing,
population numbers of SSEA3þ /Annexin Vþ , of which represents
‘apoptotic stem cells’, in Dox-treated N2102Ep and TERA1 were
two-fold increased approximately in comparison with the controls
(Figure 2A and B). On the other hand, the numbers of SSEA3þ /
Annexin Vþ population were not increased in the pluripotent
stem cell lines NTERA2 and H7 ES cells (Figure 3A and B). These
results suggest that DNMT3B might prevent apoptosis in the
human nullipotent EC cells N2102Ep and TERA1, but not in
pluripotent NTERA2 and human ES cells.
Aza-dC induces apoptosis of pluripotent stem cells NTERA2
through DNMT3B. We found that Aza-dC treatment led to an
increase in the numbers of SSEA3þ /Annexin Vþ population in
N2102Ep, TERA1, NTERA2 and H7 (Figure 2), suggesting that the
apoptotic effect of Aza-dC on the stem cells is a general feature as
in mouse ES cells (Juttermann et al, 1994; Oka et al, 2005). We also
observed that in pluripotent NTERA2 cells treated with Aza-dC, a
further depletion of DNMT3B by shRNAi resulted in a reduction in
the SSEA3þ /Annexin Vþ population compared with cells treated
with Aza-dC alone (Figure 3A). In contrast, the numbers of
SSEA3þ /Annexin Vþ population of N2102Ep, TERA1 and H7
treated with Aza-dC were similar between without or with
DNMT3B silencing (Figure 2A and B and Figure 3B). These
results suggest that DNMT3B mediates an induction of apoptosis
induced by Aza-dC in the pluripotent stem cells NTERA2 but not
in N2102Ep, TERA1 and human ES cells.
Aza-dC induces differentiation of human ES cells through
DNMT3B. As Aza-dC has been originally reported to induce
cellular differentiation (Taylor and Jones, 1979; Jones and Taylor,
1980), we next asked whether Aza-dC might induce differentiation
of human teratocarcinoma stem cells N2102Ep and TERA1 and
pluripotent stem cells NTERA2 and H7. Treatment with Aza-dC
resulted in an increase in numbers of SSEA3 /Annexin V cells,
of which represents ‘non-apoptotic differentiated cells’, in
pluripotent NTERA2 and H7 (Figure 3). On the other hand, the
numbers of SSEA3 /Annexin V cells in N2102Ep and TERA1
were not increased by Aza-dC treatment (Figure 2A and B). This
result indicates that Aza-dC induces differentiation of pluripotent
NTERA2 and H7 cells.
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Figure 1. DNMT3B is not only important for clonal ability of stem cells,
but also mediates a reduction of clonal ability induced by Aza-dC
treatment. (A) Western blotting of DNMT3B in N2102Ep, TERA1,
NTERA2 and H7 ES cells with doxycycline (Dox) treatment to
knockdown DNMT3B. (B) Cloning efficiency was performed in
N2102Ep, TERA1, NTERA2 and H7 cells with doxycycline (Dox) and/or
Aza-dC treatment. Data are represented as mean±s.d.; n¼3;
*Po0.05.
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To establish whether DNMT3B mediates differentiation of
pluripotent NTERA2 and H7 induced by Aza-dC, we treated the
cells with Aza-dC in the absence or presence of DNMT3B silencing.
In human ES cells H7 treated with Aza-dC, a further depletion of
DNMT3B by shRNAi resulted in less cell number of SSEA3 /
Annexin V population than cells treated with Aza-dC only
(Figure 3B). In contrast, the number of SSEA3 /Annexin V cells
of NTERA2 treated with Aza-dC was similar between without or
with DNMT3B silencing (Figure 3A). This result suggests that
DNMT3B mediates an induction of differentiation induced by Aza-
dC in human ES cells but not in pluripotent stem cells NTERA2.
Consistent with flow cytometry analysis, we found that Aza-dC
treatment led to a reduction of the expression level of stem cell-
associated genes OCT4, NANOG and SOX2 in pluripotent NTERA2
and H7 ES cells (Figure 4). In contrast, Aza-dC treatment did not
downregulate expression of the stem cell genes in the nullipotent EC
cells N2102Ep and TERA1. Further, silencing of DNMT3B in Aza-
dC-treated NTERA2 and H7 resulted in a higher expression of
OCT4, NANOG and SOX2 compared with cells treated with Aza-dC
alone. This result indicates that DNMT3B might also mediate
downregulation of OCT4, NANOG and SOX2 in pluripotent
NTERA2 and H7 ES cells induced by Aza-dC.
Resistance of Aza-dC-induced apoptosis of differentiated
teratocarcinoma stem cells. Although many human EC cell lines
fail to differentiate after manipulation of culture conditions, we have
previously shown that N2102Ep and TERA1 do differentiate
following knockdown of OCT4 using siRNA (Matin et al, 2004;
Andrews et al, 2005). To test whether these differentiated derivative
cells undergo apoptosis by Aza-dC induction similar to that
observed in their stem cell parents (Figure 2A and B), we have
established shRNAi-inducible OCT4 knockdown cell lines of
N2102Ep and TERA1 (Figure 5A). Consistent with the previous
works, the inducible OCT4 knockdown N2102Ep and TERA1 by
shRNAi showed an upregulation of genes representing trophoblastic
and endodermal lineages, indicating their differentiation (Figure 5B).
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Dose-response experiments were then performed to ascertain
whether the sensitivity to Aza-dC is altered in differentiated versus
undifferentiated cells. We found that undifferentiated N2102Ep and
TERA1 show IC50 at approximately 5 nM, whereas differentiated
cells, as induced by Dox treatment to knockdown OCT4, show IC50
at 100 nM (Figure 5C). This result indicates that the cancer stem cells
are more sensitive to Aza-dC than their differentiated derivatives.
Flow cytometric analysis reveals that silencing of OCT4 gave rise
to more Annexin Vþ cells (Figure 2C and D), suggesting that
OCT4 might inhibit apoptosis of nullipotent EC cells. We found
that expression of DNMT3B was diminished by silencing of OCT4
(Figure 5A) supporting the role of DNMT3B in preventing
apoptosis in N2102Ep and TERA1 (Figure 2A and B). Next, upon
Aza-dC treatment we compared the level of Annexin Vþ cells of
NTERA2 DNMT3B shRNAi
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the stem cells and their OCT4 knockdown differentiated cells to
ascertain whether Aza-dC is able to induce apoptosis of the
differentiated cancer cells. Although Aza-dC treatment increased
the number of Annexin Vþ cells of EC cells, it failed to do so in the
OCT4 knockdown differentiated cancer cells (Figure 2C and D).
This result suggests that the apoptotic response induced by Aza-dC
is specific to undifferentiated stem cells. Collectively, our results
imply that Aza-dC selectively target the stem cell component of
teratocarcinoma.
DISCUSSION
Human teratocarcinoma consists of EC cells, which represent the
stem cells of the tumours, and their differentiated cells or teratoma.
The majority of human EC cells do not differentiate in culture,
therefore they are considered as nullipotent stem cells (Andrews
et al, 2005). DNMT3B is one of the most highly expressed
transcripts found in EC cells including N2102Ep and TERA1
(Sperger et al, 2003). We report in the present study that the clonal
ability of EC cells is dependent on DNMT3B expression
(Figure 1B). DNMT3B is also necessary to prevent apoptosis in
EC cells N2102Ep and TERA1, but not in pluripotent NTERA2
and ES cells (Figure 2A and B and Figure 3A and B). DNMT3B has
been reported as an oncogene in many somatic cancers (Beaulieu
et al, 2002; Rhee et al, 2002; Lin et al, 2006; Linhart et al, 2007;
Kurita et al, 2010; Sandhu et al, 2011). Our study, therefore,
provides evidence that DNMT3B might act as an oncogene in
nullipotent EC cells. Similar to our finding, knockdown of
DNMT3L, which is another DNA methyltransferase without the
catalytic activity, induces two-fold increase of numbers of
apoptotic cells in human EC cells (Minami et al, 2010). As
DNMT3L interacts with and promotes de novo DNA methylation
activity of DNMT3B (Suetake et al, 2004), the role of these two
genes might be functionally related in tumorigenesis of
teratocarcinoma.
We find that Aza-dC induces apoptosis of nullipotent EC cells
(N2102Ep and TERA1) as well as pluripotent EC and ES cells
(NTERA2 and H7). Our result supports a recent study, which
shows that Aza-dC treatment at the concentration of 10 nM is
enough to attenuate clonal ability and to induce apoptosis of
NTERA2 (Beyrouthy et al, 2009). This concentration is
approximately 100–1000 fold lower than that used to induce
cytotoxicity of somatic cells (Beyrouthy et al, 2009). We show that
Aza-dC induces not only apoptosis, but also differentiation of
pluripotent NTERA2 and H7 (Figure 3A and B). Our results
suggest that the epigenetic drug Aza-dC alters fates of pluripotent
stem cells by driving these cells toward differentiation and
apoptosis. On the other hand, it induces nullipotent EC cells
N2102Ep and TERA1 to undergo only apoptosis but not
differentiation.
We show in this study that DNMT3B mediates apoptosis induced
by Aza-dC in pluripotent NTERA2 (Figure 3A), whereas it mediates
downregulation of SSEA3 expression induced by Aza-dC in
pluripotent H7 ES cells (Figure 3B). Nonetheless, DNMT3B has a
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role in Aza-dC-induced downregulation of OCT4, NANOG and
SOX2 expression in both NTERA2 and H7 (Figure 4). Our results
support previous findings that DNMT3B mediates the effects of
Aza-dC to induce apoptosis in mouse ES cells and human
pluripotent stem cells NTERA2 (Oka et al, 2005; Beyrouthy et al,
2009; Biswal et al, 2012). In contrast to the pluripotent stem cells, as
DNMT3B is important to prevent apoptosis of N2102Ep and
TERA1 (Figure 2A and B), knockdown of DNMT3B in the
nullipotent N2102Ep and TERA1 might not allow the nullipotent
EC cells to encounter the apoptotic effect of Aza-dC. Hence, the
sensitivity of Aza-dC toward apoptotic or differentiation responses is
not always determined by the expression level of DNMT3B.
A mechanism underlying cytotoxicity induced by Aza-dC has been
proposed to occur through a covalent trapping of DNA methyl-
transferases (Juttermann et al, 1994), which then induces DNA
mutagenicity (Jackson-Grusby et al, 1997). Given that cell cycle
profile is not different in mouse ES cells depleted for DNA
methyltransferases (Oka et al, 2005), an incorporation activity of
Aza-dC into genomic DNA of the cells might be similar. Therefore,
the higher apoptosis induced by Aza-dC treatment in control than
in DNMT3B knockdown cells, which was observed only in NTERA2
but not other cell lines, could be explained by the formation of
covalent adduct between Aza-dC-DNMT3B at genomic level rather
than by difference in cell cycle profile especially in S phase.
We have previously reported that transient siRNA silencing of
OCT4 in nullipotent stem cells including the N2102Ep and TERA1
induced them to differentiate (Matin et al, 2004; Andrews et al,
2005). We show that silencing of OCT4 led to apoptosis of
N2102Ep and TERA1 (Figure 2C and D). The increase in apoptotic
cells might be due to a reduction of DNMT3B level (Figure 5A), as
DNMT3B prevents apoptosis in the nullipotent EC cells (Figure 2A
and B). Because somatic cells respond poorly to Aza-dC compared
with teratocarcinoma stem cells (Beyrouthy et al, 2009), we
induced differentiation of N2102Ep and TERA1 using shRNAi-
inducible OCT4 knockdown, and found that differentiated OCT4
knockdown cells respond poorly to the epigenetic drug Aza-dC
(Figure 2C and D). As Aza-dC is a nucleoside analogue that can be
incorporated into DNA during S phase, the higher cytotoxicity
observed in the nullipotent EC cells than in their OCT4 knock-
down differentiated cells might be due to a higher cell division rate
of the cancer stem cells. Our study, therefore, provides evidence
that EC cells but not their differentiated derivatives are sensitive to
the epigenetic drug Aza-dC. Therefore, using Aza-dC in clinical
trials of patients with teratocarcinoma should be cautious, in which
the drug will target only EC cells, but might act poorly against
differentiated teratoma tissues. A recent study has also suggested
the ability of Aza-dC to target cancer stem-like cells (Tsai et al,
2012). Thus further investigations on the anticancer stem cell
property of Aza-dC toward other types of cancers, which are
developed from cancer stem cells or cancer initiating cells, will be
important to translate the use of this epigenetic drug into clinic.
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